Osteonecrosis development by tooth extraction in zoledronate treated mice is inhibited by active vitamin D analogues, anti-inflammatory agents or antibiotics

[1]  A. Ishisaki,et al.  Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner , 2021, Calcified Tissue International.

[2]  Byoung-Eun Yang,et al.  Various Therapeutic Methods for the Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) and Their Limitations: A Narrative Review on New Molecular and Cellular Therapeutic Approaches , 2021, Antioxidants.

[3]  K. Miyamoto,et al.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw , 2020, Journal of Bone and Mineral Metabolism.

[4]  N. Amizuka,et al.  Frequent Administration of Abaloparatide Shows Greater Gains in Bone Anabolic Window and Bone Mineral Density in Mice: A Comparison with Teriparatide. , 2020, Bone.

[5]  J. Yamashita,et al.  Effect of bisphosphonates on healing of tooth extraction wounds in infectious osteomyelitis of the jaw. , 2020, Bone.

[6]  K. Miyamoto,et al.  Vitamin D protects against immobilization-induced muscle atrophy via neural crest-derived cells in mice , 2020, Scientific Reports.

[7]  J. Bilezikian,et al.  Controversies in the treatment of postmenopausal osteoporosis: How long to treat with bisphosphonates? , 2020, Archives of endocrinology and metabolism.

[8]  Megumi Kishimoto,et al.  Which symptoms negatively affect the oral health-related quality of life in patients with osteonecrosis of the jaw? , 2020, Oral surgery, oral medicine, oral pathology and oral radiology.

[9]  Jörg Menche,et al.  Environmental arginine controls multinuclear giant cell metabolism and formation , 2020, Nature Communications.

[10]  A. Hokugo,et al.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice. , 2019, Bone.

[11]  H. Goldvaser,et al.  Role of Bisphosphonates in Breast Cancer Therapy , 2019, Current Treatment Options in Oncology.

[12]  V. Costa,et al.  The Multifaceted Role of Annexin A1 in Viral Infections , 2023, Cells.

[13]  I. Kaplan,et al.  Comparison of the histopathological characteristics of osteomyelitis, medication-related osteonecrosis of the jaw, and osteoradionecrosis. , 2019, International journal of oral and maxillofacial surgery.

[14]  A. Taguchi,et al.  Long waiting time before tooth extraction may increase delayed wound healing in elderly Japanese , 2018, Osteoporosis International.

[15]  B. Djulbegovic,et al.  Bisphosphonates for Patients Diagnosed With Multiple Myeloma. , 2018, JAMA.

[16]  N. Park,et al.  Removal of Pre-Existing Periodontal Inflammatory Condition before Tooth Extraction Ameliorates Medication-Related Osteonecrosis of the Jaw-Like Lesion in Mice. , 2018, The American journal of pathology.

[17]  H. Kishimoto,et al.  Long-term oral bisphosphonates delay healing after tooth extraction: a single institutional prospective study , 2018, Osteoporosis International.

[18]  S. Kuroshima,et al.  Prevalence of bisphosphonate-related osteonecrosis of the jaw-like lesions is increased in a chemotherapeutic dose-dependent manner in mice. , 2018, Bone.

[19]  R. Eastell,et al.  Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density , 2018, Osteoporosis International.

[20]  H. Takayanagi,et al.  Host defense against oral microbiota by bone-damaging T cells , 2018, Nature Communications.

[21]  S. Kuroshima,et al.  Transplantation of Noncultured Stromal Vascular Fraction Cells of Adipose Tissue Ameliorates Osteonecrosis of the Jaw–Like Lesions in Mice , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  S. Kuroshima,et al.  Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice , 2018, Journal of Bone and Mineral Metabolism.

[23]  K. Tsuchiya,et al.  Management of Osteoporosis in Chronic Kidney Disease , 2017, Internal medicine.

[24]  P. Anderson.  Vitamin D Activity and Metabolism in Bone , 2017, Current Osteoporosis Reports.

[25]  K. Pittman,et al.  Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures , 2017, Asia-Pacific journal of clinical oncology.

[26]  K. Miyamoto,et al.  Elevation of pro-inflammatory cytokine levels following anti-resorptive drug treatment is required for osteonecrosis development in infectious osteomyelitis , 2017, Scientific Reports.

[27]  N. Park,et al.  IL‐36 Induces Bisphosphonate‐Related Osteonecrosis of the Jaw‐Like Lesions in Mice by Inhibiting TGF‐β‐Mediated Collagen Expression , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  K. Kaur,et al.  Plasticity of Myeloid Cells during Oral Barrier Wound Healing and the Development of Bisphosphonate-related Osteonecrosis of the Jaw* , 2016, The Journal of Biological Chemistry.

[29]  S. Dry,et al.  Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  Y. Toyama,et al.  Vitamin D Deficiency with High Intact PTH Levels is More Common in Younger than in Older Women: A Study of Women Aged 39-64 Years. , 2016, The Keio journal of medicine.

[31]  R. Adler.  Duration of anti-resorptive therapy for osteoporosis , 2016, Endocrine.

[32]  Fahad M. Alshahrani,et al.  How Long to Treat with Bisphosphonates , 2015 .

[33]  F. Bauss,et al.  Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. , 2015, Bone.

[34]  K. Kaur,et al.  Erratum: Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: Role in osteoclast-mediated NK cell activation , 2015, Oncotarget.

[35]  S. Dry,et al.  OPG‐Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  R. Dresner-Pollak,et al.  The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells , 2015, PloS one.

[37]  K. Kaur,et al.  Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: Role in osteoclast-mediated NK cell activation , 2015, Oncotarget.

[38]  J. Sayre,et al.  Osteonecrosis of the Jaw Developed in Mice , 2015, The Journal of Biological Chemistry.

[39]  Y. Toyama,et al.  The Vitamin D Analogue ED71 but Not 1,25(OH)2D3 Targets HIF1α Protein in Osteoclasts , 2014, PloS one.

[40]  S. Dry,et al.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model. , 2014, Bone.

[41]  H. Saya,et al.  TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state , 2014, Oncogene.

[42]  B. Stack,et al.  Is Bisphosphonate-Related Osteonecrosis of the Jaw an Infection? A Histological and Microbiological Ten-Year Summary , 2014, International journal of dentistry.

[43]  J. Bartova,et al.  Porphyromonas gingivalis: Major Periodontopathic Pathogen Overview , 2014, Journal of immunology research.

[44]  G. Morgan,et al.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Aspenberg,et al.  Prevention of osteonecrosis of the jaw by mucoperiosteal coverage in a rat model. , 2013, International journal of oral and maxillofacial surgery.

[46]  F. Saad,et al.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. , 2012 .

[47]  T. Mizoguchi,et al.  Daily administration of eldecalcitol (ED‐71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  E. McCloskey,et al.  Bisphosphonates in oncology. , 2011, Bone.

[49]  H. Chtioui,et al.  Teriparatide therapy for osteonecrosis of the jaw. , 2011, The New England journal of medicine.

[50]  G. Gazelle,et al.  Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. , 2011, The oncologist.

[51]  T. Braun,et al.  Teriparatide and osseous regeneration in the oral cavity. , 2010, The New England journal of medicine.

[52]  H. Yatani,et al.  Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice , 2010, Journal of Bone and Mineral Metabolism.

[53]  T. Taniguchi,et al.  1-Alpha, 25-dihydroxy vitamin D3 inhibits osteoclastogenesis through IFN-beta-dependent NFATc1 suppression , 2009, Journal of Bone and Mineral Metabolism.

[54]  C. Weiner,et al.  Chronic Hypoxemia Absent Bacterial Infection Is One Cause of the Fetal Inflammatory Response Syndrome (FIRS) , 2009, Reproductive sciences.

[55]  I. Reid.  Osteonecrosis of the jaw: who gets it, and why? , 2009, Bone.

[56]  B. Clarke,et al.  Bisphosphonates: mechanism of action and role in clinical practice. , 2008, Mayo Clinic proceedings.

[57]  M. Allen,et al.  Bisphosphonates and Osteonecrosis of the Jaw: Moving from the Bedside to the Bench , 2008, Cells Tissues Organs.

[58]  J. Reginster,et al.  Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. , 2008, Bone.

[59]  H. Tan,et al.  WHO GETS IT AND WHY , 2007 .

[60]  J. Berenson.  Myeloma bone disease. , 2005, Best practice & research. Clinical haematology.

[61]  S. Holt,et al.  Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. , 2005, Periodontology 2000.

[62]  L. Xing,et al.  Required and nonessential functions of nuclear factor-kappa B in bone cells. , 1999, Bone.

[63]  M. Monden,et al.  Profiles of circulating inflammatory- and anti-inflammatory cytokines in patients with hemolytic uremic syndrome due to E. coli O157 infection. , 1998, Cytokine.

[64]  Ulrich Siebenlist,et al.  Requirement for NF-κB in osteoclast and B-cell development , 1997 .

[65]  A. Leonardi,et al.  Requirement for NF-kappaB in osteoclast and B-cell development. , 1997, Genes & development.

[66]  Sheila J. Jones,et al.  Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. , 1988, Endocrinology.

[67]  A. Norman,et al.  Studies on vitamin D (calciferol) and its analogues. 10. Side-chain analogues of 25-hydroxyvitamin D3. , 2002, Journal of medicinal chemistry.